Latest Breaking News On - Global head of drug development - Page 3 : comparemela.com

Evotec Creates long-term Growth Opportunities by Initiating Campus Levi-Montalcini in Verona

Evotec Creates long-term Growth Opportunities by Initiating Campus Levi-Montalcini in Verona
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Bruxelles capitaleEl salvadorCiriaco maraschielloGiuseppe leviStanley cohenWerner lanthalerLuria nobelRenato dulbecco nobelCalissanop rita levi montalciniVolker braunRita levi montalciniViktor hamburgerGabriele hansenUniversity of turinHead of global corporate communications marketingGlobal head of drug development

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program | Antibodies

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

United statesUnited kingdomLookeren campagneBeovu baselJohn tsaiWorld health organizationGlobal head of drug developmentHealth qual life outcomesCanadian drug expert committee recommendationNational eye instituteNational health insurance pricingEuropean society of retina specialistsCanadian agency for drugsNj novartis pharmaceuticals corporationTechnologies in healthLancet glob health

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

NOVARTIS AG CHF0.50(REGD) Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1 In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept

United statesUnited kingdomIsabella zinckRachel finkLookeren campagneThomas hungerbuehlerAmy wolfSamir shahJulie masowBeovu baselSloan simpsonJohn tsaiNovartis division communicationsWorld health organizationGlobal head of drug developmentNovartis external communications

Novartis Pharma AG: Novartis reports one year results of Phase III MERLIN study evaluating Beovu every four week dosing and provides update on Beovu clinical program

Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept

United statesUnited kingdomIsabella zinckRachel finkLookeren campagneThomas hungerbuehlerAmy wolfSamir shahJulie masowBeovu baselSloan simpsonJohn tsaiNovartis division communicationsWorld health organizationGlobal head of drug developmentNovartis external communications

Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

/PRNewswire/ Today, Novartis reported the first interpretable year one results of the Phase III MERLIN study, a two-year study initiated in H2 2018,.

United statesUnited kingdomLookeren campagneBeovu baselJohn tsaiHealth qual life outcomesNational eye instituteNational health insurance pricingTechnologies in healthWorld health organizationGlobal head of drug developmentCanadian drug expert committee recommendationExchange commissionNj novartis pharmaceuticals corporationNovartis pharmaceuticals corporationCanadian agency for drugs